Product Description Compound Specifications Full Name: Retatrutide Analog (GLP3-R) Sequence Type: Multi-receptor incretin-associated peptide analog Target Pathways: GLP-1, GIP, and glucagon receptor signaling Molecular Weight: ~4731 g/mol Structure Notes: Structurally modified peptide analog incorporating targeted amino acid substitutions and lipidation to support prolonged receptor interaction and signaling stability Overview GLP3-R is a multi-receptor peptide analog frequently incorporated into experimental models examining how coordinated GLP-1 , GIP , and glucagon receptor signaling influences nutrient-responsive metabolic systems
Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer
Available under brand names including Wegovy (FDA-approved for weight loss) and Ozempic (FDA-approved for diabetes, not for weight loss), semaglutide mimics the action of naturally occurring GLP-1, a hormone released by the intestine in response to food intake
Start Your Weight Loss Path Today Take the first step toward a healthier future
Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier